Dow Up0.25% Nasdaq Up0.65%

More On PLI.TO



News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


ProMetic Life Sciences Inc. (PLI.TO)

2.91 Down 0.04(1.36%) 4:00PM EDT
ProfileGet Profile for:
ProMetic Life Sciences Inc.
440 Boulevard Armand-Frappier
Suite 300
Laval, QC H7V 4B4
Canada - Map
Phone: 450-781-0115
Fax: 450-781-4477

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bio separations, plasma-derived therapeutics, and small-molecule drugs. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. It operates in two segments, Small Molecule Therapeutics and Protein Technology. The Small Molecule Therapeutics segmentÂ’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. The Protein Technology segment provides Plasma Protein Purification System, a solution for plasma fractionation, as well as for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on ProMetic Life Sciences Inc.

Key Executives 
Mr. Pierre Laurin B.Sc.Pharm., M.Sc., 55
Chief Exec. Officer, Pres, Non-Independent Director and Member of Strategy Devel. & Asset Monetization Committee
Mr. Gregory L. Weaver CPA, M.B.A, 60
Chief Financial Officer
Mr. Bruce Pritchard BA, CA, FIOD,
Chief Operating Officer
Mr. Patrick Sartore B.Sc., LLB,
Chief Legal Officer and Corp. Sec.
Dr. John Moran M.D., FRACP, FACP, FACPE, 70
Chief Medical Officer and Non-Independent Director
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.